These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38406164)

  • 21. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.
    Persec Z; Persec J; Sović T; Romic Z; Bosnar Herak M; Hrgovic Z
    Onkologie; 2010; 33(3):110-2. PubMed ID: 20215802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical metastases from prostate cancer: 10-year experience at a single institution.
    Vinjamoori AH; Jagannathan JP; Shinagare AB; Taplin ME; Oh WK; Van den Abbeele AD; Ramaiya NH
    AJR Am J Roentgenol; 2012 Aug; 199(2):367-72. PubMed ID: 22826398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review.
    Yang X; Jiang D; Li Y; Zhang T; Xu D; Chen X; Pang J
    Front Oncol; 2021; 11():659442. PubMed ID: 33981608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumothorax as a Presenting Clinical Manifestation of Metastatic Prostate Cancer.
    Chiang KH; Hung SH; Chang ST
    World J Oncol; 2013 Apr; 4(2):118-121. PubMed ID: 29147342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of GOLPH3 expression in lymph node-positive prostate cancer: immunohistochemistry staining patterns and clinical significance.
    Kiełb P; Kaczorowski M; Kowalczyk K; Piotrowska A; Nowak Ł; Krajewski W; Gurwin A; Dudek K; Dzięgiel P; Hałoń A; Szydełko T; Małkiewicz B
    Front Oncol; 2023; 13():1265788. PubMed ID: 37790749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
    Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Supraclavicular lymphadenopathy as the initial presentation of metastatic prostate cancer: A case report and review of literature.
    Chan G; Domes T
    Can Urol Assoc J; 2013; 7(5-6):E433-5. PubMed ID: 23826058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Left axillary lymphadenopathy as initial presentation of metastatic prostate cancer: A rare case report.
    Mremi A; Mbwambo OJ; Bright F; Mbwambo JS; Mteta KA; Ngowi BN
    Int J Surg Case Rep; 2021 May; 82():105889. PubMed ID: 33878669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cervical lymphadenopathy as initial presentation of metastatic prostate cancer: A retrospective study of five cases and literature review.
    Liu Y; Dai Z; Hao J; Wang L; Liu Z
    Front Surg; 2023; 10():1081951. PubMed ID: 36793314
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
    Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
    Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
    Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small cell carcinoma of the prostate presenting with skin metastasis: a case report.
    Cecen K; Karadag MA; Demir A; Kocaaslan R
    J Med Case Rep; 2014 May; 8():146. PubMed ID: 24885487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy.
    Mitsui Y; Sadahira T; Maruyama Y; Wada K; Tanimoto R; Sugimoto M; Araki M; Watanabe M; Yanai H; Watanabe T; Nasu Y
    Acta Med Okayama; 2018 Dec; 72(6):605-609. PubMed ID: 30573917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients.
    Ganeshan D; Aparicio AM; Morani A; Kundra V
    AJR Am J Roentgenol; 2017 Aug; 209(2):327-332. PubMed ID: 28590819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.